HISTOPATHOLOGICAL FEATURES AND GRADING IN RHABDOMYOSARCOMAS OF CHILDHOOD

Rhabdomyosarcoma represents a large group of soft tissue sarcomas disp laying heterogeneous histopathological features. In addition to their histopathological classification, the variable expression of a number of histopathological features may contribute to the heterogeneity and may be related to prognosis. Tissue sections of 113 well-documented, p rotocol-treated patients with long term follow-up (mean 6 years) were analysed by a panel of four paediatric pathologists. The following fea tures were assessed: presence of rhabdomyoblasts, degree of maturation of rhabdomyoblasts, heterogeneous maturation patterns, mitotic activi ty, tumour necrosis, myxoid component, and septa. A scoring system was allocated to each index. High degree of maturation (amount of cytopla sm greater than surface area of the nucleus), absence of tumour necros is (< 10% of tumour surface), and absence of septa (< 10% of tumour su rface) significantly correlated with a favourable clinical course. Rep roducibility in the assessment of these three features was good: mean ic varying from 0.53 to 0.64. A rhabdomyosarcoma score function for su rvival was defined by: (- 0.27 x degree of maturation score) + (0.007 x percentage septated area) + (0.031 x percentage tumour necrosis). Ba sed on the score a two-grade system was elaborated, i.e. grade I (scor e < -0.20) v. grade II (score greater than or equal to -0.20). Rhabdom yosarcoma grade appeared to be the best factor in predicting patients survival: 69% long-term survival in patients with grade I v. 33% in pa tients with grade II (P = 0.0001). Moreover, this grading system was s hown to have discriminative power within the group of patients with em bryonal rhabdomyosarcoma: patients with a grade I tumour fared signifi cantly better than those with a grade II tumour (63% v. 41% long-term survival, P = 0.03). This study, therefore, demonstrated the prognosti c value of this grading system and its useful application within the g roup of patients with embryonal rhabdomyosarcomas.